Propranolol
Propranolol be a medication of de beta blocker class.[1][2][3] E be used to treat high blood pressure, sam types of irregular heart rate, thyrotoxicosis, capillary hemangiomas, akathisia, performance anxiety, den essential tremors, [2][4][5][6] as well as to prevent migraine headaches, den to prevent further heart problems insyd those plus angina anaa previous heart attacks.[2] Dem fi take am orally, rectally, anaa by intravenous injection.[2][7] De formulation wey dem dey take orally dey cam in short-acting den long-acting versions.[2] Propranolol dey appear insyd de blood after 30 minutes wey e get a maximum effect between 60 den 90 minutes wen dem take am orally.[2][8]
Common side effects dey include nausea, abdominal pain, den constipation.[2] E fi worsen de symptoms of asthma.[2] Propranolol fi cause harmful effects for de baby if dem take am during pregnancy;[9] however, ein use during breastfeeding generally be considered to be safe.[10] E be a non-selective beta blocker wich dey work by blocking β-adrenergic receptors.[2]
Na dem patent propranolol insyd 1962 wey na dem approve am for medical use insyd 1964.[11] E dey on de World Health Organization's List of Essential Medicines.[12] Propranolol be available as a generic medication.[2] Insyd 2023, na e be de 69th most commonly prescribed medication insyd de United States, plus more dan 9 million prescriptions.[13][14]
References
[edit | edit source]- ↑ Srinivasan AV (2019). "Propranolol: A 50-Year Historical Perspective". Ann Indian Acad Neurol. 22 (1): 21–26. doi:10.4103/aian.AIAN_201_18. PMC 6327687. PMID 30692755.
- 1 2 3 4 5 6 7 8 9 10 "Propranolol hydrochloride". Monograph. The American Society of Health-System Pharmacists. Archived from the original on 1 January 2015. Retrieved 1 January 2015.
- ↑ "Inderal (propranolol hydrochloride) Tablets" (PDF). www.accessdata.fda.gov.
- ↑ Davidson JR (2006). "Pharmacotherapy of social anxiety disorder: what does the evidence tell us?". The Journal of Clinical Psychiatry. 67 (Suppl 12): 20–26. doi:10.1016/j.genhosppsych.2005.07.002. PMID 17092192.
- ↑ Chinnadurai S, Fonnesbeck C, Snyder KM, Sathe NA, Morad A, Likis FE, McPheeters ML (February 2016). "Pharmacologic Interventions for Infantile Hemangioma: A Meta-analysis" (PDF). Pediatrics. 137 (2) e20153896. doi:10.1542/peds.2015-3896. PMID 26772662. S2CID 30459652.
- ↑ Blaisdell, G. D. (July 1994). "Akathisia: A Comprehensive Review and Treatment Summary". Pharmacopsychiatry (in English). 27 (4): 139–146. doi:10.1055/s-2007-1014294. ISSN 0176-3679. PMID 7972345.
- ↑ Kalam MN, Rasool MF, Rehman AU, Ahmed N (2020). "Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review". Curr Drug Metab. 21 (2): 89–105. doi:10.2174/1389200221666200414094644. PMID 32286940.
- ↑ Bryson PD (1997). Comprehensive review in toxicology for emergency clinicians (3 ed.). Washington, DC: Taylor & Francis. p. 167. ISBN 978-1-56032-612-0. Archived from the original on 24 March 2017.
- ↑ "Prescribing medicines in pregnancy database". Australian Government. 3 March 2014. Archived from the original on 8 April 2014. Retrieved 22 April 2014.
- ↑ Briggs GG, Freeman RK, Yaffe SJ (2011). Drugs in pregnancy and lactation: a reference guide to fetal and neonatal risk (9th ed.). Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins. p. 1226. ISBN 978-1-60831-708-0. Archived from the original on 14 February 2017.
- ↑ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 460. ISBN 978-3-527-60749-5.
- ↑ World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- ↑ "Top 300 of 2023". ClinCalc. Archived from the original on 12 August 2025. Retrieved 12 August 2025.
- ↑ "Propranolol Drug Usage Statistics, United States, 2013 - 2023". ClinCalc. Retrieved 18 August 2025.
Read further
[edit | edit source]- Stapleton MP (1997). "Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology". Texas Heart Institute Journal. 24 (4): 336–342. PMC 325477. PMID 9456487.
External links
[edit | edit source]- CS1 English-language sources (en)
- CS1:Vancouver names with accept markup
- Commons category link from Wikidata
- 1-Naphthyl compounds
- 5-HT1A agonists
- 5-HT1A antagonists
- 5-HT1B antagonists
- 5-HT2B antagonists
- Anxiolytics
- Beta blockers
- Disulfiram-like drugs
- Drugs wey AstraZeneca develop
- Isopropylamino compounds
- N-isopropyl-phenoxypropanolamines
- Naphthol ethers
- Norepinephrine reuptake inhibitors
- Scottish inventions
- Sodium channel blockers
- World Health Organization essential medicines
- Products dem introduce insyd 1964
- Translated from MDWiki